Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,397 across all filing types
Latest filing 2019-08-28 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Fasenra granted US Orphan Drug Designation for
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's news service (RNS). The content is a press release announcing that the FDA granted Orphan Drug Designation (ODD) to Fasenra for eosinophilic oesophagitis (EoE). This is a specific, timely corporate announcement regarding regulatory status and product development, not a comprehensive annual report (10-K), an interim report (IR), or a transcript (CT). Since it is a general regulatory announcement that doesn't fit into the more specific categories like Director's Dealing (DIRS) or Dividend Notice (DIV), the most appropriate classification is the general Regulatory Filings category (RNS), as it is explicitly distributed via RNS.
2019-08-28 English
Breztri Aerosphere Phase III ETHOS trial met
Earnings Release Classification · 99% confidence The document begins with an 'RNS Number' and is dated August 28, 2019. It contains a headline announcing positive Phase III trial results for a drug ('Breztri Aerosphere') and includes quotes from company executives and investigators. The text concludes with contact information for Media Relations and Investor Relations, and explicitly states: 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a regulatory news service announcement, which falls under the general category of Regulatory Filings (RNS), as it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change (MANG). FY 2019
2019-08-28 English
ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN NON-DIALYSIS-DEPEND
Regulatory Filings
2019-08-22 English
ASTRAZENECA AGREES TO BUY US FDA PRIORITY REVIEW
Regulatory Filings
2019-08-22 English
Roxadustat approved in China for the treatment of
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 8927J' and is dated August 22, 2019. It announces a significant corporate event: the marketing authorisation of a drug (Roxadustat) in China by the National Medical Products Administration. The text concludes with boilerplate information referencing RNS, the London Stock Exchange, and the Financial Conduct Authority (FCA). This structure is characteristic of a general regulatory news service announcement, which fits the Regulatory Filings (RNS) category, as it is not a specific financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). It is a general regulatory update.
2019-08-22 English
AstraZeneca agrees to buy US FDA Priority Review
M&A Activity Classification · 99% confidence The document begins with an 'RNS Number' and is dated, indicating it is a regulatory announcement. The content describes a specific corporate transaction: AstraZeneca agreeing to buy a US FDA Priority Review Voucher (PRV) from Sobi for $95m. This is a material event announcement. Since it is a general regulatory announcement that doesn't fit specific categories like Director's Dealing (DIRS), Capital Change (CAP), or M&A (TAR), and it is clearly distributed via the RNS system (London Stock Exchange's news service), the most appropriate classification is the general Regulatory Filings category (RNS). The document length is short (3172 chars) and it is a direct announcement, not an announcement *about* a report, so RPA is not the best fit.
2019-08-22 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.